Maxim - TACTI-002 Head & Neck Cancer Study is Expanding, Data Updates Over 2020 – Reiterate Buy
January 10th 2020
Maxim - Runway Through CY20, Upcoming Catalysts ShouldContinue to Drive a Higher Valuation
October 28th 2019
goetzpartners securities - TACTI-mel final data confirm efficacy signals
This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.